AJANTPHARM2021-04-012021-06-30in-bse-fin:OneOperatingExpenses01Member AJANTPHARM2021-04-012021-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AJANTPHARM2021-04-012021-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares AJANTPHARM 2021-04-01 2022-03-31 2021-07-21 INR Crores First quarter Single segment PHARMACEUTICAL 2021-04-01 2021-06-30 Unaudited Consolidated 7479900000.00 326300000.00 7806200000.00 1872300000.00 365100000.00 -520800000.00 1579900000.00 15100000.00 308800000.00 1981300000.00 5601700000.00 2204500000.00 0.00 2204500000.00 447200000.00 19800000.00 467000000.00 0.00 1737500000.00 0.00 0.00 0.00 0.00 1737500000.00 -23300000.00 1714200000.00 1714200000.00 0.00 173900000.00 2 20.08 20.08 0.00 0.00 20.08 20.08 1. The above consolidated financial results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 29 July 2021. The statutory auditors have expressed unmodified opinion. The review report has been filed with the stock exchange and is available on company website. 2. The consolidated unaudited financial results of the Company, its wholly owned subsidiaries and step-down subsidiary (“the Group”) have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest. 3. The figures for the quarter ended 31 March 2021 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figure upto the third quarter ended 31 December 2020. 4. The Group continued to take into account the possible impacts of COVID-19 in preparation of the financial statements, including but not limited to its assessment of liquidity and going concern assumption, recoverable values of its financial and non-financial assets, impact on revenues and on costs. The Group has been able to effectively manage the operations till now with appropriate safety precautions, without any significant impact of COVID-19 on the business. The Group will continue to closely monitor future economic conditions to ensure business continuity. 5. The Group operates exclusively in one reportable business segment i.e., Pharmaceuticals . 6. The Financial Results are available for investors at the company's website www.ajantapharma.com, www.nseindia.com and www.bseindia.com. Other Expenses 1981300000.00